PRODUCT INFORMATION



Stiripentol-d_o

Item No. 28506

CAS Registry No.:	1185239-64-8	
Formal Name:	1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-d ₃ -	
	1-penten-5,5,5-d ₃ -3-ol	Л
MF:	$C_{14}H_9D_9O_3$	
FW:	243.3	
Chemical Purity:	≥98% (Stiripentol)	
Deuterium		
Incorporation:	≥99% deuterated forms (d ₁ -d ₉); ≤1% d ₀	
Supplied as:	A solid	
Storage:	-20°C	
Stability:	≥4 years	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Stiripentol-d_q is intended for use as an internal standard for the quantification of stiripentol (Item No. 17781) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Stiripentol-do is supplied as a solid. A stock solution may be made by dissolving the stiripentol-do in the solvent of choice, which should be purged with an inert gas. Stiripentol- d_o is soluble in chloroform.

Description

Stiripentol is a third-generation antiepileptic compound.¹ It is a positive allosteric modulator of $GABA_A$ receptors, potentiating GABA-mediated activation to a greater extent in receptors expressing α_3 subunits and to a lower extent in those containing β_1 or ϵ subunits.² It also inhibits GABA reuptake *in vitro* and increases the release of GABA in neonatal rat hippocampal slices.^{1,3} Stiripentol (500 μ M) inhibits lactate dehydrogenase (LDH), blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human LDH1 and LDH5.⁴ Formulations containing stiripentol have been used in the adjunctive treatment of seizures associated with Dravet syndrome.

References

- 1. Luszczki, J.J. Third-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactions. Pharmacol. Rep. 61(2), 197-216 (2009).
- 2. Fisher, J.L. The anti-convulsant stiripentol acts directly on the $GABA_{A}$ receptor as a positive allosteric modulator. Neuropharmacology 56(1), 190-197 (2009).
- 3. Quilichini, P.P., Chiron, C., Ben-Ari, Y., et al. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA_A-receptor channels. Epilepsia 47(4), 704-716 (2006).
- 4. Sada, N., Lee, S., Katsu, T., et al. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science 347(6228), 1362-1367 (2015).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 10/26/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM